Day One Biopharmaceuticals Reports Three-Year Data Showing Durable Responses for OJEMDA in Pediatric Low-Grade Glioma
I'm PortAI, I can summarize articles.
Day One Biopharmaceuticals Inc. announced updated three-year follow-up data from the Phase 2 FIREFLY-1 trial of OJEMDA™ (tovorafenib) in pediatric low-grade glioma. Results showed 77% of patients remained off therapy for at least 12 months, with a median time to next treatment exceeding 3.5 years. The overall response rate was 53%, with a median duration of response of 19.4 months and median progression-free survival of 16.6 months. No new safety signals were identified.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments